Combination of Cisplatin and Lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases

Highlights • Most malignant mesotheliomas are not curable despite multimodal treatment. • Treatment with cisplatin and the novel compound lurbinectedin seems promising. • The course of two cases is presented.

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2016-12, Vol.102, p.136-138
Main Authors: Metaxas, Yannis, MD, Cathomas, Richard, Mark, Michael, von Moos, Roger
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carbolines - administration & dosage
Carbolines - adverse effects
Cisplatin - administration & dosage
Cisplatin - adverse effects
Clinical Trials, Phase I as Topic
Combined Modality Therapy
Hematology, Oncology and Palliative Medicine
Heterocyclic Compounds, 4 or More Rings - administration & dosage
Heterocyclic Compounds, 4 or More Rings - adverse effects
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - radiotherapy
Lung Neoplasms - surgery
Lurbinectedin
Male
Mesothelioma
Mesothelioma - drug therapy
Mesothelioma - radiotherapy
Mesothelioma - surgery
Mesothelioma, Malignant
Palliative Care - methods
Palliative chemotherapy
Pleural Neoplasms - drug therapy
Pleural Neoplasms - radiotherapy
Pleural Neoplasms - surgery
Prognosis
Pulmonary/Respiratory
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Most malignant mesotheliomas are not curable despite multimodal treatment. • Treatment with cisplatin and the novel compound lurbinectedin seems promising. • The course of two cases is presented.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2016.07.012